David L. Snitman
Keine laufenden Positionen mehr
Profil
David L.
Snitman was the founder of Array BioPharma, Inc. (founded in 1998) where he held the title of Executive Vice President-Business Development in 2015.
He previously worked as an Associate Director-New Products & Technology at Amgen, Inc. and as a Director at BaroFold, Inc. Dr. Snitman received his undergraduate degree from Northeastern University and his doctorate from The University of Colorado.
Ehemalige bekannte Positionen von David L. Snitman
| Unternehmen | Position | Ende |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Gründer | 30.06.2015 |
| AMGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
BaroFold, Inc.
 BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Direktor/Vorstandsmitglied | - |
Ausbildung von David L. Snitman
| Northeastern University | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
BaroFold, Inc.
BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Health Technology |
